Breaking News

Galena, Dr. Reddy's Enter Strategic NeuVax Pact

By Kristin Brooks | January 14, 2014

To expand development of breast cancer drug

Galena Biopharma and Dr. Reddy's Laboratories Ltd. have entered a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax is the immunodominant nonapeptide derived from the HER2 protein, a target for therapeutic intervention in breast cancer. Based on a successful Phase II trial, which achieved its primary endpoint of disease-free survival, the FDA granted NeuVax a Special Protocol Assessment (SPA) for a Phase III study.
 
"This partnership with Dr. Reddy's is consistent with our strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy," said Mark J. Ahn, Ph.D., president and chief executive officer of Galena Biopharma. "The gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population, if approved."
 
G V Prasad, chairman and chief executive officer, Dr. Reddy's, said, "The partnership accelerates our strong commitment to innovation and efforts to bring newer options for cancer patients. We are delighted with our partnership with Galena Biopharma and we believe NeuVax can be a good potential treatment option to prevent the recurrence of breast and gastric cancer."

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016